Q-omics provides the consensus-scored PSKH1 profile across patient tissues and cancer cell-line models. PSKH1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PSKH1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, PSKH1 RNA expression shows 19,350 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, THCA, and ACC as cancer lineages where PSKH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSKH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSKH1 survival associations across molecular data types. PSKH1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSKH1 RNA expression–survival associations across cancer types. High PSKH1 expression shows unfavorable associations in BLCA, ACC and LUSC, but favorable associations in KIRP, SCLC and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PSKH1 RNA expression.
This table summarizes PSKH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PSKH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSKH1 shows lower tumor expression in THCA, KIRC, BRCA, LUAD and UCEC and higher tumor expression in LIHC. The THCA box plot shows higher PSKH1 RNA expression in normal versus tumor tissue (log2 FC = −0.968, t-test p < 0.001).
This table shows molecular features associated with PSKH1 in patient tissues and cancer cell lines. In patient samples, PSKH1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PSKH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
